These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 7584503)

  • 21. Construction and characterization of a Fab recombinant protein for Japanese encephalitis virus neutralization.
    Wu SC; Lin YJ; Chou JW; Lin CW
    Vaccine; 2004 Nov; 23(2):163-71. PubMed ID: 15531033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic and fluorescence studies of affinity maturation in related antibodies.
    Pauyo T; Hilinski GJ; Chiu PT; Hansen DE; Choi YJ; Ratner DI; Shah-Mahoney N; Southern CA; O'Hara PB
    Mol Immunol; 2006 Mar; 43(7):812-21. PubMed ID: 16137768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of a recombinant single-chain variable-fragment (scFv) antibody against sulfoglycolipid.
    Cheng X; Zhang Y; Kotani N; Watanabe T; Lee S; Wang X; Kawashima I; Tai T; Taniguchi N; Honke K
    J Biochem; 2005 Mar; 137(3):415-21. PubMed ID: 15809345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular selection of human antibodies with an unconventional bacterial B cell antigen.
    Sasano M; Burton DR; Silverman GJ
    J Immunol; 1993 Nov; 151(10):5822-39. PubMed ID: 8228264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview and discovery of IgNARs and generation of VNARs.
    Nuttall SD
    Methods Mol Biol; 2012; 911():27-36. PubMed ID: 22886244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Purification of recombinant humanized anti-HBsAg Fab antibody by affinity chromatography].
    Deng N; Chen WY; Xiang JJ; Rao GR; Tang Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Sep; 20(5):575-7. PubMed ID: 15367351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineering aggregation-resistant antibodies.
    Perchiacca JM; Tessier PM
    Annu Rev Chem Biomol Eng; 2012; 3():263-86. PubMed ID: 22468604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential binding of heavy chain variable domain 3 antigen binding fragments to protein A chromatography resins.
    Bach J; Lewis N; Maggiora K; Gillespie AJ; Connell-Crowley L
    J Chromatogr A; 2015 Aug; 1409():60-9. PubMed ID: 26189670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of recombinant antibody fragments for troponin I measurements.
    Altshuler EP; Vylegzhanina AV; Katrukha IA; Bereznikova AV; Serebryanaya DV
    Biochemistry (Mosc); 2012 Dec; 77(12):1362-7. PubMed ID: 23244731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanobodies®: proficient tools in diagnostics.
    Huang L; Muyldermans S; Saerens D
    Expert Rev Mol Diagn; 2010 Sep; 10(6):777-85. PubMed ID: 20843201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecularly defined antibody conjugation through a selenocysteine interface.
    Hofer T; Skeffington LR; Chapman CM; Rader C
    Biochemistry; 2009 Dec; 48(50):12047-57. PubMed ID: 19894757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent Developments Toward Antibody Engineering and Affinity Maturation.
    Rathore AS; Sarker A; Gupta RD
    Protein Pept Lett; 2018; 25(10):886-896. PubMed ID: 30255742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography.
    Verheesen P; ten Haaft MR; Lindner N; Verrips CT; de Haard JJ
    Biochim Biophys Acta; 2003 Dec; 1624(1-3):21-8. PubMed ID: 14642809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-structure-based design of pharmacological agents.
    Dougall WC; Peterson NC; Greene MI
    Trends Biotechnol; 1994 Sep; 12(9):372-9. PubMed ID: 7765190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant single-chain and disulfide-stabilized Fv immunotoxins for cancer therapy.
    Niv R; Segal D; Reiter Y
    Methods Mol Biol; 2003; 207():255-68. PubMed ID: 12412479
    [No Abstract]   [Full Text] [Related]  

  • 36. Structural aspects of conformational changes in ligand binding by antibody fragments.
    Edmundson AB; Guddat LW; Shan L; Fan ZC; Hanson BL
    Res Immunol; 1994 Jan; 145(1):56-61. PubMed ID: 8008970
    [No Abstract]   [Full Text] [Related]  

  • 37. NANOBODY
    Kunz S; Durandy M; Seguin L; Feral CC
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dependence of the specific activity of antitetanus immunoglobulin on the degree of its fragmentation].
    Gavrilenkova VIu; Selezneva VP; Runova VF; Kargina TM
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Mar; (3):68-71. PubMed ID: 2939668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications.
    Braun J; Saxon A; Wall R; Morrison SL
    West J Med; 1992 Aug; 157(2):158-68. PubMed ID: 1441467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting antibody-based technologies to manage environmental pollution.
    Harris B
    Trends Biotechnol; 1999 Jul; 17(7):290-6. PubMed ID: 10370236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.